(NASDAQ: CTKB) Cytek Biosciences's forecast annual revenue growth rate of 7.46% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.09%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.
Cytek Biosciences's revenue in 2025 is $197,050,000.On average, 3 Wall Street analysts forecast CTKB's revenue for 2025 to be $25,961,715,382, with the lowest CTKB revenue forecast at $25,281,175,522, and the highest CTKB revenue forecast at $26,343,846,176. On average, 3 Wall Street analysts forecast CTKB's revenue for 2026 to be $28,586,093,923, with the lowest CTKB revenue forecast at $27,193,729,381, and the highest CTKB revenue forecast at $29,501,459,932.
In 2027, CTKB is forecast to generate $31,976,380,622 in revenue, with the lowest revenue forecast at $30,220,884,166 and the highest revenue forecast at $33,731,877,079.